No Data
Lushang Freda Pharmaceutical (600223): Continuously optimizing product lines and channel layout, exploring new growth points.
Seeking stable growth in adversity. In the first three quarters of 2024, the company achieved revenue of 2.803 billion yuan, a year-on-year decrease of -17.45%; broken down by business, in the first three quarters of 2024, the company's cosmetic/pharmaceutical/raw materials and additives business.
Lushang Freda (600223) 2024 third quarter report review: short-term performance under pressure, new product upgrades expected to boost volume.
The company disclosed its performance report for the third quarter of 24 years: 2024Q1-3 revenue of 2.803 billion yuan (-17.45%, representing the year-on-year growth rate, the same below), net profit attributable to the mother of 0.171 billion yuan (-28.09%), non-net profit attributable to the mother.
Lushang Freda (600223): The growth rate of cosmetics in the off-season is slowing down. Pharmaceutical & raw materials sectors are exerting strength.
Event: The company released the third quarter report of 2024: In 2024 Q1-Q3, the company achieved revenue of 2.803 billion yuan, -17.45% year-on-year, achieved net income attributable to mother of 0.171 billion yuan, -28.09% year-on-year, achieved deductions.
Lushang Freda Pharmaceutical (600223): Consolidating internal strength during the transformation period, looking forward to impressive performance during the November 11 shopping festival.
The company released the third quarter report of 2024: revenue of 2.803 billion yuan for the first three quarters of 2024 (-17.4% year-on-year), net income attributable to the parent company of 0.171 billion yuan (-28.1% year-on-year), non-GAAP net income 1.
lushang freda pharmaceutical (600223): continuous adjustment, looking forward to acceleration
The company released its Q1-Q3 financial report for the 24th year, with performance meeting expectations. The revenue for 24Q1-Q3 was 2.803 billion yuan, down by 17.45% year-on-year; the net income attributable to the parent company was 0.171 billion yuan, down by 28.09% year-on-year, mainly due to the divestment of the real estate business last year.
Lushang Freda Pharmaceutical (600223): Cosmetic business adjustment period leads to income pressure. Cost reduction and efficiency improvement support the optimization of gross profit structure.
Compared to the real estate financial data from the same period last year, there were some fluctuations, but the core main business remained stable. The company's revenue for the first three quarters was 2.803 billion yuan, a decrease of 17.45% year-on-year; achieving a net income attributable to the parent company of 0.171 billion yuan, a decrease of 28.09% year-on-year.
No Data
No Data